Dimerix Limited (ASX:DXB) Insider Purchases A$57,562.65 in Stock

Dimerix Limited (ASX:DXB) insider Nina Webster acquired 127,917 shares of the business’s stock in a transaction dated Friday, January 31st. The shares were bought at an average price of A$0.45 ($0.28) per share, with a total value of A$57,562.65 ($36,202.92).

Dimerix Stock Performance

The company has a current ratio of 9.49, a quick ratio of 7.91 and a debt-to-equity ratio of 0.82.

About Dimerix

Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. The company develops DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 which is in phase 2 clinical trial for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for chronic obstructive pulmonary disease, as well as develops proprietary receptor- HIT assay technology.